Cholesterol emboli syndrome (CES) occurs when multiple cholesterol crystals break off from atherosclerotic plaques and become lodged in circulation, causing end-organ damage for the organs that rely on the circulatory system, leading to inflammation. There is no distinct therapy for cholesterol emboli syndrome and anti-inflammatory treatments are not proven to be helpful. Research is investigating if thrombolytic or anticoagulant therapy causes CES, yet a consensus has not been reached. Therefore, treatment is focus on management of atherosclerosis and arterial ischemia.
Cholesterol Embolus Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Cholesterol Embolus Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 985 products for the study of Cholesterol Embolus Syndrome that can be applied to Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.